Your session is about to expire
← Back to Search
M1774 + ZEN-3694 for Ovarian and Endometrial Cancer
Study Summary
This trial tests if M1774+ZEN-3694 can safely stop tumor growth in ovarian/endometrial cancer patients. It has already been seen to be more effective than either drug alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the population of participants in this research trial?
"Affirmative. Information hosted on clinicaltrials.gov indicates that this medical investigation, which was first shared on the 27th of May 2024, is currently recruiting participants. A total of 60 individuals are sought from a solitary medical centre."
Is enrolment into this trial still available for interested participants?
"Affirmative. The clinical trial, which was initially posted on May 27th 2024 and revised most recently on September 15th 2023, is seeking additional participants for the study as indicated by data found on clinicaltrials.gov. 60 individuals are needed from 1 site to participate in this experiment."
How does the safety profile of tuvusertib, ZEN-3694 and other related BET bromodomain inhibitors compare to current therapies?
"Our organisation's rankings place the security of this treatment combination (tuvusertib, BET bromodomain inhibitor ZEN-3694) at a 1 due to its Phase 1 status. This implies that there is minimal evidence indicating both safety and efficacy."
What are the overarching objectives of this experiment?
"This clinical trial aims to evaluate DLTs in the first 28 days of treatment, as well as c-myc expression via Digital Spatial Profiling (DSP) using tumor samples. GammaH2AX and objective response rate will also be assessed by DSP and Response Evaluation Criteria in Solid Tumors (RECIST). Descriptive statistics such as mean, standard deviation, median are employed to summarise data; one-sided Wilcoxon signed rank tests are applied to compare pre-treatment vs on-treatment gammaH2AX expressions from patients treated at RP2D with evaluable bio specimens."
Share this study with friends
Copy Link
Messenger